Mezigdomide (MEZI) plus dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): results from the CC-92480-MM-002 trial

被引：0
|
作者：
Raab, Marc S. [1 ]
Oriol, Albert [2 ]
Sandhu, Irwindeep [3 ]
White, Darrell [4 ,5 ]
Leblanc, Richard [6 ]
Raje, Noopur [7 ]
Ocio, Enrique M. [8 ]
Perrot, Aurore [9 ]
Facon, Thierry [10 ]
Rodriguez, Cesar [11 ]
Waesch, Ralph [12 ]
Amatangelo, Michael [13 ]
Zhou, Zehua [13 ]
Wang, Yue [13 ]
Civardi, Tiziana [14 ]
Koo, Phillip [13 ]
Maciag, Paulo [13 ]
Zhu, Daniell [13 ]
Katz, Jessica [13 ]
Richardson, Paul G. [15 ]
机构：
[1] Univ Klinikum Heidelberg, Heidelberg, Germany
[2] Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol & Josep Carreras Inst, Badalona, Spain
[3] Univ Alberta, Edmonton, AB, Canada
[4] Dalhousie Univ, Halifax, NS, Canada
[5] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada
[6] Univ Montreal, Hop Maisonneuve Rosemont, Montreal, PQ, Canada
[7] Massachusetts Gen Hosp, Boston, MA USA
[8] Hosp Univ Marques de Valdecilla IDIVAL, Santander, Spain
[9] Inst Univ Canc Toulouse Oncopole, Toulouse, France
[10] Univ Lille, Ctr Hosp Univ CHU Lille, Serv Malad Sang, Lille, France
[11] Icahn Sch Med Mt Sinai, New York, NY USA
[12] Univ Freiburg, Dept Med, Med Ctr, Freiburg, Germany
[13] Bristol Myers Squibb, Princeton, NJ USA
[14] Celgene Int Sarl, Boudr, Switzerland
[15] Dana Farber Canc Inst, Boston, MA USA
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2024年 / 47卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
335
引用
收藏
页码：115 / 115
页数：1
相关论文
共 50 条
  • [21] Iberdomide (IBER) plus dexamethasone (DEX) in patients with relapsed/refractory multiple myeloma (RRMM): a safety analysis from the CC-220-MM-001 trial
    van de Donk, Niels
    White, Darrell
    Lipe, Brea
    Khan, Abdullah
    Niesvizky, Ruben
    Oriol, Albert
    Mesa, Mercedes Gironella
    Anwer, Faiz
    Bhutani, Manisha
    McClune, Brian
    Singhal, Seema
    Cheng, Yiming
    Hamada, Izumi
    Jin, Kexin
    Solomon, Thomas
    Hong, Kevin
    Amin, Alpesh
    Maciag, Paulo
    Lonial, Sagar
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S214 - S215
  • [22] Low vs high dose carfilzomib (Cfz) with dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): Results of SWOG S1304.
    Ailawadhi, Sikander
    Sexton, Rachael
    Lentzsch, Suzanne
    Abidi, Muneer Hyder
    Voorhees, Peter Michael
    Cohen, Adam D.
    Rohren, Eric
    Heitner, Stephen
    Kelly, Kevin
    Mackler, Niklas J.
    Baer, David M.
    Hoering, Antje
    Hoering, Antje
    Durie, Brian G.
    Orlowski, Robert Z.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [23] Melflufen and dexamethasone (dex) plus bortezomib (BTZ) or daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) (OP-104)
    Pour, Ludek
    Efebera, Yvonne
    Granell, Miquel
    Hajek, Roman
    Oriol, Albert
    Delaunay, Jacques
    Le Du, Katell
    Eveillard, Jean-Richard
    Karlin, Lionel
    Maisnar, Vladimir
    Martinez-Lopez, Joaquin
    Mateos, Maria-Victoria
    Moreb, Jan
    Ribrag, Vincent
    Richardson, Paul G.
    Straub, Jan
    Byrne, Catriona
    Jacques, Christian
    Zubair, Hanan
    Ocio, Enrique
    CANCER RESEARCH, 2019, 79 (13)
  • [24] Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Dose-Expansion Phase of the CC-220-MM-001 Trial
    Lonial, Sagar
    Popat, Rakesh
    Hulin, Cyrille
    Jagannath, Sundar
    Oriol, Albert
    Richardson, Paul G.
    Facon, Thierry
    Weisel, Katja
    Larsen, Jeremy T.
    Minnema, Monique C.
    Abdallah, Al-Ola
    Badros, Ashraf Z.
    Knop, Stefan
    Stadtmauer, Edward A.
    Chen, Min
    Nguyen, Tuong Vi
    Amin, Alpesh
    Kueenburg, Elisabeth
    Peluso, Teresa
    van de Donk, Niels W. C. J.
    BLOOD, 2021, 138
  • [25] First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
    Richardson, Paul G.
    Vangsted, Annette J.
    Ramasamy, Karthik
    Trudel, Suzanne
    Martinez, Joaquin
    Mateos, Maria-Victoria
    Rodriguez Otero, Paula
    Lonial, Sagar
    Popat, Rakesh
    Oriol, Albert
    Karanes, Chatchada
    Orlowski, Robert Z.
    Berdeja, Jesus G.
    Wong, Lilly
    Shi, Chenyang
    Lamba, Manisha
    Barnett, Evelyn
    Pierce, Daniel W.
    Pourdehnad, Michael
    Bahlis, Nizar J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [26] Phase II study of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with relapsed or relapsed and refractory multiple myeloma (MM)
    Anderson, K. C.
    Jagannath, S.
    Jakubowiak, A.
    Lonial, S.
    Raje, N.
    Schlossman, R.
    Munshi, N.
    Knight, R.
    Esseltine, D.
    Richardson, P. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [27] A randomized, multicenter, phase (Ph) III study comparing carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (Dex) to LEN and Dex in patients (Pts) with relapsed multiple myeloma (MM).
    Moreau, P.
    Palumbo, A. P.
    Stewart, A. K.
    Rajkumar, V.
    Jakubowiak, A. J.
    Halka, K.
    Goranov, S.
    Bumbea, H.
    Pendergrass, K. B.
    Lupu, A.
    Dimopoulos, A.
    Rocafiguera, A. O.
    Gandhi, J. G.
    Mihaylov, G.
    Masszi, T.
    Matous, J.
    Fonseca, G.
    Bryce, R.
    Siegel, D. S. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [28] Impact of renal impairment (RI) on pharmacokinetics (PK) and clinical outcomes with mezigdomide plus dexamethasone (DEX) in relapsed/refractory multiple myeloma (RRMM)
    Trudel, Suzanne
    Bahlis, Nizar J.
    Popat, Rakesh
    Mateos, Maria-Victoria
    Vangsted, Annette J.
    Ramasamy, Karthik
    Martinez-Lopez, Joaquin
    Quach, Hang
    Orlowski, Robert Z.
    Burnett, Joseph
    Gaudy, Allison
    Chen, Wencong
    Gong, Jing
    Hadala, Joseph T.
    Donahue, Cynthia
    Koo, Phillip
    Zhu, Yue
    Katz, Jessica
    Richardson, Paul G.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [29] Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Outcomes in pts refractory to lenalidomide (LEN) and/or bortezomib (BORT).
    Vij, Ravi
    Richardson, Paul Gerard Guy
    Jagannath, Sundar
    Siegel, David Samuel DiCapua
    Baz, Rachid C.
    Srinivasan, Shankar
    Larkins, Gail
    Zaki, Mohamed H.
    Hussein, Mohamad A.
    Anderson, Kenneth Carl
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [30] Phase I trial of suberoylanilide hydroxamic acid (SAHA) plus bortezomib (Bort) in relapsed multiple myeloma (MM) patients (pts).
    Badros, Ashraf
    Philip, S.
    Niesvizky, R.
    Goloubeva, O.
    Harris, C.
    Zweibel, J.
    Wright, J.
    Burger, A.
    Grant, S.
    Baer, M. K.
    Egorin, M. J.
    BLOOD, 2007, 110 (11) : 354A - 354A
12345